Discover
NEJM AI Grand Rounds
NEJM AI Grand Rounds
Author: NEJM Group
Subscribed: 341Played: 4,327Subscribe
Share
NEJM AI Grand Rounds is a product of NEJM Group, a division of the Massachusetts Medical Society. Copyright ©2026. All rights reserved.
Description
NEJM AI Grand Rounds, hosted by Arjun (Raj) Manrai, Ph.D. and Andrew Beam, Ph.D., features informal conversations with a variety of unique experts exploring the deep issues at the intersection of artificial intelligence, machine learning, and medicine. You’ll learn how AI will change clinical practice and healthcare, how it will impact the patient experience, and about the people who are pushing for innovation. Whether you are an AI researcher or a practicing clinician, these conversations will enlighten and surprise you as we journey through this very exciting field. Produced by NEJM Group.
49 Episodes
Reverse
A patient misses a lung cancer screening. A hospital has sent reminders, but the appointment still never happens. Munjal Shah, co-founder and CEO of Hippocratic AI, believes voice-based clinical agents may help health systems reach patients who otherwise fall through the cracks. Yet the most revealing part of his argument is not about speed or scale. It is about limits. Shah describes delaying a product launch while his team tested safety, building multiple safeguards into patient conversations, and refusing to describe an AI agent as a nurse. He also recounts a hospice-related use case where the technology fell short of the emotional support families needed. For practicing physicians, these examples sharpen an urgent question: what evidence should health systems demand before allowing AI to engage directly with patients? The conversation moves from medication safety checks to follow-up outreach and the distinction between automated communication and human care. Where might AI extend clinical capacity — and where should clinicians insist that people remain at the center?
Transcript.
Dr. Michał Nedoszytko, clinician scientist at Abridge and interventional cardiologist, has spent two decades building software alongside clinical practice. He explains how AI can help physicians gather better information before an encounter, improve the quality of conversations with patients, and prototype solutions to problems that clinicians experience every day. Nedoszytko argues that medical training gives physicians lived knowledge that they can bring to building software. Yet he draws a firm distinction between making software and making software safe. In regulated clinical environments, engineers, privacy protections, and rigorous delivery remain indispensable. As AI assumes more analytical and administrative work, he hopes medicine becomes more grounded in its human purpose: clinicians closer to patients, present in the moment, rather than focused on screens and documentation.
Transcript.
The promise of medical AI is not simply better performance — it is better care grounded in evidence patients and clinicians can trust. Dr. Xiao Liu, a clinician and medical AI researcher affiliated with the University of Birmingham and Microsoft AI, has spent her career asking what rigorous evaluation should look like as new technologies move from publications into practice. She describes reporting guidelines as tools for transparency rather than prescriptions and explains why seeing product development from inside industry changed her understanding of implementation. Looking ahead, Liu imagines a medical profession in which readily available knowledge shifts physicians toward a more interpersonal role: accompanying patients through uncertainty, deterioration, treatment failure, recovery, and life-changing diagnoses. At the same time, she sees AI opening new scientific possibilities by revealing biomarkers, disease phenotypes, and treatment-response patterns that current medical categories may miss. The challenge is to preserve rigor without letting familiar methods prevent medicine from learning something genuinely new.
Transcript.
A patient can deteriorate while the warning signs remain buried in a noisy electronic record. Dr. Suchi Saria, Founder and CEO of Bayesian Health and a faculty member at Johns Hopkins University, has spent her career trying to surface those signals sooner. She explains why a strong retrospective model is only the starting point — and why prospective validation, workflow integration, physician adoption, monitoring, and financial sustainability determine whether clinical AI ever reaches patients. Her work on early sepsis recognition became personal after she lost her nephew to the condition, turning an academic agenda into an urgent effort to prevent failures to rescue. Saria also challenges the current center of gravity in health care AI: tools increasingly prepare for visits, transcribe conversations, and support billing, while comparatively few directly help clinicians care for patients. She envisions a third modality of medicine alongside drugs and devices — rigorous, software-based interventions that identify when to act, what to do, and for whom.
Transcript.
Brandon Rice believes that improving health care sometimes means improving the systems behind it. Through his work at Weave, he focuses on modernizing the regulatory infrastructure that helps bring new medicines to market. He discusses the challenge of organizing scientific knowledge, communicating with regulators, and navigating processes that can span more than a decade. His vision is that AI can reduce administrative burden while preserving the rigor required for patient safety and scientific progress.
Transcript.



